HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ATP4B
ATPase H+/K+ transporting subunit beta
Chromosome 13 · 13q34
NCBI Gene: 496Ensembl: ENSG00000186009.5HGNC: HGNC:820UniProt: P51164
29PubMed Papers
20Diseases
17Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Transporter
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
protein bindingsodium ion export across plasma membraneintracellular potassium ion homeostasisATPase activator activitygastroesophageal reflux diseasegastric ulcerduodenal ulcerPeptic ulcer
✦AI Summary

ATP4B encodes the β-subunit of the gastric H+/K+-ATPase proton pump, which transports H+ ions in exchange for K+ ions across the apical membrane of parietal cells 1. The protein functions as a structural and regulatory component that stabilizes the pump in its outward-facing (E2) conformation, preventing reverse transport and ensuring efficient gastric acid secretion [UniProt annotation]. ATP4B expression is progressively downregulated in gastric pathology, including atrophic gastritis, intestinal metaplasia, and early gastric cancer, correlating with malignant transformation and poor tumor differentiation 213. Molecular silencing of ATP4B in gastric cancer involves intragenic DNA hypermethylation and histone deacetylation, mechanisms reversible by epigenetic inhibitors 45. Functionally, ATP4B acts as a tumor suppressor—its restoration suppresses gastric cancer cell proliferation, migration, and invasion while inducing apoptosis through regulation of mitochondrial metabolism 1. Clinically, ATP4B serves multiple roles: methylated ATP4B DNA in plasma is a potential gastric cancer biomarker 4, autoantibodies against ATP4B distinguish corpus atrophic gastritis with superior diagnostic performance (AUC 0.838) compared to pepsinogen I 6, and ATP4B downregulation correlates with mucosal acidity compromise detectable by novel AI-assisted pH mapping systems for early cancer detection 3.

Sources cited
1
MNNG-induced gastric intestinal metaplasia involves down-regulation of ATP4B alongside up-regulation of intestinal markers CDX2 and MUC2
PMID: 39153963
2
ATP4B downregulation in gastric cancer involves intragenic DNA methylation; methylated ATP4B DNA in plasma is a potential biomarker
PMID: 23317218
3
ATP4B acts as a tumor suppressor; its restoration suppresses gastric cancer cell proliferation, migration, invasion and promotes apoptosis via mitochondrial metabolism regulation
PMID: 33111209
4
Autoantibodies against ATP4B have superior diagnostic performance (AUC 0.838, 77% sensitivity, 88% specificity) for detecting corpus atrophic gastritis compared to pepsinogen I
PMID: 33031196
5
ATP4B is identified as a hub gene for gastric cancer diagnosis through machine learning analysis with support vector machine achieving 0.93 AUC on test and 0.99 AUC on external validation
PMID: 35812327
6
ATP4B silencing in gastric cancer involves intragenic DNA hypermethylation and histone H3K9 deacetylation, reversible by epigenetic inhibitors; restoration enhances chemotherapeutic response
PMID: 28281974
7
ATP4B expression levels correlate with pepsin in vocal cord leukoplakia and contribute to dysplasia progression through regulation of lysosomal acidification
PMID: 37264983
8
ATP4B is progressively downregulated in gastric mucosal atrophy, intestinal metaplasia, and early gastric cancer; pH mapping based on ATP4B changes achieved 87.79% sensitivity and 85.04% specificity for EGC detection
PMID: 41114471
Disease Associationsⓘ20
gastroesophageal reflux diseaseOpen Targets
0.61Moderate
gastric ulcerOpen Targets
0.61Moderate
duodenal ulcerOpen Targets
0.60Moderate
Peptic ulcerOpen Targets
0.60Moderate
Zollinger-Ellison SyndromeOpen Targets
0.59Moderate
esophagitisOpen Targets
0.58Moderate
peptic esophagitisOpen Targets
0.56Moderate
Helicobacter pylori infectious diseaseOpen Targets
0.56Moderate
osteoarthritisOpen Targets
0.54Moderate
rheumatoid arthritisOpen Targets
0.54Moderate
peptic ulcer diseaseOpen Targets
0.53Moderate
angina pectorisOpen Targets
0.53Moderate
transient ischemic attackOpen Targets
0.53Moderate
ankylosing spondylitisOpen Targets
0.52Moderate
gastric cancerOpen Targets
0.51Moderate
hemorrhageOpen Targets
0.50Moderate
spondylitisOpen Targets
0.50Moderate
ulcer diseaseOpen Targets
0.50Moderate
Gastric Mucosa-Associated Lymphoid Tissue LymphomaOpen Targets
0.47Moderate
thrombotic diseaseOpen Targets
0.46Moderate
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets17
ABEPRAZANApproved
Potassium-transporting ATPase inhibitor
Peptic ulcer
DEXLANSOPRAZOLEApproved
Potassium-transporting ATPase inhibitor
gastroesophageal reflux disease
ESOMEPRAZOLEApproved
Potassium-transporting ATPase inhibitor
gastroesophageal reflux disease
ESOMEPRAZOLE MAGNESIUMApproved
Potassium-transporting ATPase inhibitor
gastric ulcer
ESOMEPRAZOLE SODIUMApproved
Potassium-transporting ATPase inhibitor
gastroesophageal reflux disease
ESOMEPRAZOLE STRONTIUMApproved
Potassium-transporting ATPase inhibitor
Zollinger-Ellison Syndrome
ILAPRAZOLEApproved
Potassium-transporting ATPase inhibitor
gastroesophageal reflux disease
LANSOPRAZOLEApproved
Potassium-transporting ATPase inhibitor
OMEPRAZOLEApproved
Potassium-transporting ATPase inhibitor
peptic ulcer disease
OMEPRAZOLE MAGNESIUMPhase III
Potassium-transporting ATPase inhibitor
PANTOPRAZOLEApproved
Potassium-transporting ATPase inhibitor
gastroesophageal reflux disease
PANTOPRAZOLE SODIUMApproved
Potassium-transporting ATPase inhibitor
Zollinger-Ellison Syndrome
RABEPRAZOLEApproved
Potassium-transporting ATPase inhibitor
gastroesophageal reflux disease
RABEPRAZOLE SODIUMApproved
Potassium-transporting ATPase inhibitor
Zollinger-Ellison Syndrome
TEGOPRAZANApproved
Potassium-transporting ATPase blocker
Peptic ulcer
VONOPRAZANApproved
Potassium-transporting ATPase inhibitor
Peptic ulcer
VONOPRAZAN FUMARATEApproved
Potassium-transporting ATPase inhibitor
myocardial infarction
Related Genes
ATP1A1Protein interaction100%FXYD2Protein interaction100%PPA1Protein interaction96%PPA2Protein interaction93%LHPPProtein interaction92%CBLIFProtein interaction88%
Tissue Expression6 tissues
Brain
100%
Liver
13%
Ovary
8%
Lung
5%
Heart
0%
Bone Marrow
0%
Gene Interaction Network
Click a node to explore
ATP4BATP1A1FXYD2PPA1PPA2LHPPCBLIF
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt P51164
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
1.04LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.75 [0.56–1.04]
RankingsWhere ATP4B stands among ~20K protein-coding genes
  • #12,102of 20,598
    Most Researched29
  • #100of 1,025
    FDA-Approved Drug Targets16 · top 10%
  • #10,363of 17,882
    Most Constrained (LOEUF)1.04
Genes detectedATP4B
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Modeling gastric intestinal metaplasia in 3D organoids using nitrosoguanidine.
PMID: 39153963
J Mol Cell Biol · 2024
1.00
2
Intragenic DNA methylation concomitant with repression of ATP4B and ATP4A gene expression in gastric cancer is a potential serum biomarker.
PMID: 23317218
Asian Pac J Cancer Prev · 2012
0.90
3
Tumor suppressor ATP4B serve as a promising biomarker for worsening of gastric atrophy and poor differentiation.
PMID: 33111209
Gastric Cancer · 2021
0.80
4
Autoantibodies Toward ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase Are Reliable Serological Pre-endoscopic Markers of Corpus Atrophic Gastritis.
PMID: 33031196
Clin Transl Gastroenterol · 2020
0.70
5
ESRRG, ATP4A, and ATP4B as Diagnostic Biomarkers for Gastric Cancer: A Bioinformatic Analysis Based on Machine Learning.
PMID: 35812327
Front Physiol · 2022
0.60